Clinical value of mutant P53 protein levels, purine and pyrimidine metabolizing enzymes and lysosomal enzymes in gastric cancer

ABSTRACT

Mutant P53 protein levels, purine metabolizing enzymes [adenosine deaminase[ADA], guanosine deaminase [GUA]], the pyrimidine metabolizing enzyme [cytidine deaminase [CDA]] as well as lysosomal enzymes [acid phosphatase, cathepsin D and aryl sulfatase] were determined biochemically in homogenates of 34 histologically proven gastric cancer endoscopic biopsy samples as well as 11 non-cancerous mucosal biopsy specimens from patients with localized tumors at least 2 cm apart from the lesion as a control group. From the results obtained, determination of mutant P35 protein levels in endoscopic biopsy samples before treatment is greatly helpful in detecting patients with advanced and aggressive tumors requiring special treatment modalities. Based on the results of purine and pyrimidine metabolizing enzymes, the use of new therapeutic interventions in the form of ADA inhibitors may be of a value in gastric cancer patients. The use of cathepsin D inhibitors seems to be valuable for patients with gastric cancer